Just in case you were wondering if the market is counting on a coronavirus vaccine in the nearer term, wonder no longer. (Expectations, for the moment, look to a vaccine by January, if I can judge by comments I'm seeing.) News from Pfizer (PFE) and partner BioNtech that an early stage vaccine candidate had passed […]
To subscribe to JAM you need to fill in some details below including, ahem, some info on how you'll pay us. A subscription is $199 (although if you're subscribing with one of our special offers it will be lower) for a year for ongoing and continuing access to the site. And we'll throw in the first week free! If you change your mind during that first week, just cancel your subscription from your profile page, and you won't be billed anything.
